TO THE EDITOR:
We read the recent review by Fukui et al 1 in
this journal. In their paper, they referred that the bacterial product short chain fatty acid promotes glucose regulating hormones including glucagon-like peptide 1. 1 We consider their review to be accurate and to provide further insight to the following phenomena. Mizagliflozin, a novel sodium-glucose cotransporter 1 inhibitor, suppresses the absorption of glucose and water in the intestine. 2, 3 We reported that mizagliflozin showed favourable efficacy and safety for patients with functional constipation and the risk of hypoglycaemia would be low. 4 However, the dynamic data of postprandial plasma glucose under the administration of mizagliflozin has not been shown yet.
A randomised open-label study which evaluated the effects of oral administration of mizagliflozin 5 mg or 10 mg once daily at 30 minutes after breakfast for 2 weeks on plasma glucose and spontaneous bowel movement in patients with functional constipation was conducted in Japan (ClinicalTrials.gov NCT02343978). Twenty five patients (5 mg, n = 13 and 10 mg, n = 12) were enrolled in the study. After 2-weeks, postprandial plasma glucose and insulin at 1 hour and 2 hours in 10 mg of mizagliflozin and insulin at 2 hours in 5 mg of mizagliflozin were significantly lower than those in the baseline (Table) . Areas under the curves for plasma glucose and insulin were not changed by 5 mg but significantly reduced by 10 mg of mizagliflozin (glucose, P = 0.043 and insulin, P = 0.007, onesample t test). No hypoglycemic symptoms were induced by mizagliflozin but one patient showed hypoglycemic value (58 mg/dL) of postprandial plasma glucose at 2 hours in 10 mg of mizagliflozin. The mean number of spontaneous bowel movement per week significantly increased from 2.13 (SD, 0.45) at baseline to 7.99 (9.35) at week 2 in the 5 mg group and from 1.76 (0.62) to 6.81 (4.94) in the 10 mg group.
These results suggest that mizagliflozin actually inhibits postprandial glucose absorption from the intestine and has insulinsparing effect. As Spiller 5 previously commented, altered microbiota by the luminal glucose is one of factors affecting the effect of mizagliflozin. Therefore, this study provides another evidence of the review by Fukui et al. 1 This study also supports the concept of low risk of hypoglycemia by sodium-glucose cotransporter 1 inhibitors 6 , but low value of plasma glucose in rare cases should be recognized for further clinical studies. 
